CIRM Clinical Trials
Through its strategic funding of clinical trials, CIRM helps advance innovative stem cell and gene therapy discoveries toward future treatments for patients.
CIRM funds clinical trials across a broad range of diseases and conditions that include rare and genetic disorders, treatment-resistant and refractory diseases, and many forms of cancer. Our involvement in the clinical trial process is vital to transforming potential treatments into available therapies by accelerating pathways to commercialization. Visit our Funding Opportunities page to apply for clinical trial research funding.
0
CIRM-Funded Clinical Trials
| Disease Areas | Investigator | Organization | Phase | Trial Status | Target Enrollment | Detail |
|---|---|---|---|---|---|---|
| B cell cancers Leukemia |
Thomas J Kipps | University of California, San Diego | Phase 1/2 | Active, not recruiting | 102 | |
| B cell cancers | Dr. Paul Finnegan | Angiocrine Bioscience, Inc. | Phase 3 | Closed | 130 | |
| B cell cancers Leukemia |
Dr. David B. Miklos | Stanford University | Phase 1 | Active, not recruiting | 56 | |
| B cell cancers Leukemia Leukemia, Acute Myeloid (AML) |
Dr. Matthew H Porteus | Stanford University | Phase 1 | Recruiting | 22 | |
| Blood Cancer | Dr. Edward Kavalerchik | Angiocrine Bioscience, Inc. | Phase 1 | Completed | 10 | |
| Blood Cancer | Dr. Edward Kavalerchik | Angiocrine Bioscience, Inc. | Phase 1/2 | Completed | 42 | |
| Blood Cancer | Thomas J Kipps | University of California, San Diego | Phase 1 | Completed | 26 | |
| Blood Cancer Solid Tumors |
Professor Irving L Weissman MD | Stanford University | Phase 1 | Completed | 88 | |
| Blood Cancer Bone Marrow Transplant and Viral Infection |
Michael A. Pulsipher | Children’s Hospital of Los Angeles | Phase 1/2 | Active, not recruiting | 60 | |
| HIV-related Lymphoma HIV/AIDS |
Dr Mehrdad Abedi | University of California, Davis | Phase 1/2 | Active, not recruiting | 11 | |
| Leukemia, Acute Myeloid (AML) | Dr. Colleen Delaney | Nohla Therapeutics Inc | Phase 2 | Closed | 146 | |
| Leukemia, Acute Myeloid (AML) | Mark Chao | Forty Seven Inc. | Phase 1 | Closed | 258 | |
| Leukemia, Acute Myeloid (AML) | Elizabeth Budde | City of Hope, Beckman Research Institute | Phase 1 | Launching | N/A | |
| Leukemia, Acute Myeloid (AML) | Rochelle Emery | Senti Biosciences, Inc. | Phase 1 | Launching | N/A | |
| Leukemia, Acute Myeloid (AML) | Joseph Paul Woodard | Immune-Onc Therapeutics | Phase 1 | Recruiting | 106 | |
| Multiple Myeloma | Rajesh Belani MD | Poseida Therapeutics, Inc. | Phase 1 | Closed | 105 |
